Results 141 to 150 of about 13,786,958 (257)

Differential <i>in vivo</i> tyrosine kinase inhibitor sensitivities of pediatric ABL-class Ph-like B-acute lymphoblastic leukemia. [PDF]

Hemasphere
Sharma R, Dardis JK, Mai HA, Arenas Merizalde C, van de Ven C, Bárcenas López DA, Bhatnagar S, Attarbaschi A, Boer JM, den Boer ML, Tasian SK.   +10 more
europepmc   +1 more source

From hepatic to hematopoietic: LRH‐1's expanding cellular repertoire to the immune system

The FEBS Journal, EarlyView.
The nuclear receptor LRH‐1 is a well‐characterized regulator of endodermal tissue. Yet, increasing evidence indicates that LRH‐1, although expressed at low levels, is also a critical regulator of the hematopoietic system. LRH‐1 regulates the immune system by contributing to immune cell‐specific functions.
Lukas Meisinger, Alice Wiedmann, Rayan Hassan M. Elshikhidriss, Thomas Brunner   +3 more
wiley   +1 more source

Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes. [PDF]

Blood Adv
Lee-Miller CA, Kairalla JA, Hibbitts E, Winick NJ, Rabin KR, Angiolillo A, Schore RJ, Salzer WL, Burke MJ, Loh ML, Raetz EA, Hunger SP, Devidas M, Teachey DT, Gupta S, McNeer JL.   +15 more
europepmc   +1 more source

Human APOBEC3G suppresses homologous recombination and LIG4‐independent end joining in DNA double‐strand break repair

The FEBS Journal, EarlyView.
Chromosomal DNA double‐strand breaks (DSBs) are repaired by homologous recombination and nonhomologous end joining (NHEJ). Recent work has additionally established theta‐mediated end‐joining (TMEJ) as a mechanism for DSB joining. Cells lacking NHEJ and TMEJ can repair DSBs in a homology‐dependent manner.
Shinta Saito, Miori Murayama, Usaki Arai, Sekifumi Akatsu, Ami Yamamoto, Misaki Kadoguchi, Noritaka Adachi   +6 more
wiley   +1 more source

Sinusoidal obstruction syndrome in children with B-acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin: Results from the ITCC-059 trial. [PDF]

Hemasphere
Iannicelli A, Locatelli F, Jiang Y, Ammerlaan A, Rives S, van der Sluis IM, Lindemans C, Bielorai B, Díaz de Heredia C, Lissat A, Rossig C, Petit A, Rialland Battisti F, Rizzari C, Nilsson AB, Bruno B, Rubio San Simón A, Sramkova L, Engstler G, Dirksen U, Brethon B, De Moerloose B, Pasquet M, McCarthy P, Nysom K, Halfon-Domenech C, Bertorello N, Buechner J, Bader P, Zwaan CM, Brivio E.   +30 more
europepmc   +1 more source

Role of L-asparaginase in acute lymphoblastic leukemia: focus on adult patients

, 2012
Michael E RyttingDepartment of Pediatrics and Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USAAbstract: Asparaginase preparations deplete asparagine in acute lymphoblastic leukemia (ALL) blasts.
Rytting ME
core  

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Semaphorin 4D (CD100) expression as a predictor for the response to induction therapy in pediatric patients with B-acute lymphoblastic leukemia. [PDF]

Eur J Pediatr
Elkholy RA, El Amrousy D, Elgezawy DE, Elkholy RA, Taha O, Eltoukhy AA, Elaskary E.   +6 more
europepmc   +1 more source

The Relevance of Telomerase and Telomere-Associated Proteins in B-Acute Lymphoblastic Leukemia. [PDF]

Genes (Basel), 2023
da Mota THA, Camargo R, Biojone ER, Guimarães AFR, Pittella-Silva F, de Oliveira DM.   +5 more
europepmc   +1 more source

Bringing Gene Therapy Into Real World Clinical Practice

Haemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach, Pratima Chowdary, Margareth C. Ozelo   +2 more
wiley   +1 more source